{"preliminary_commentary":{"by_channel":{"x_thread":7,"youtube":6,"podcast":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05308446\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"SWOG 2107","nct_id":"NCT05308446","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=swog-2107-nct05308446. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive encorafenib PO QD on days 1-28, cetuximab IV on days 1 and 15, and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Arm I (encorafenib, cetuximab, nivolumab)","type":"EXPERIMENTAL"},{"description":"Patients receive encorafenib PO QD on days 1-28 and cetuximab IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Arm II (encorafenib, cetuximab)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-06-01","type":"ESTIMATED"},"conditions":["Metastatic Colon Adenocarcinoma","Metastatic Rectal Adenocarcinoma","Stage III Colon Cancer AJCC v8","Stage III Rectal Cancer AJCC v8","Stage IV Colon Cancer AJCC v8","Stage IV Rectal Cancer AJCC v8","Unresectable Colon Adenocarcinoma","Unresectable Rectal Adenocarcinoma"],"enrollment":{"count":86,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Cetuximab","otherNames":["C 225","C-225","C225","Cetuxa","Cetuximab Biosimilar CDP-1","Cetuximab Biosimilar CMAB009","Cetuximab Biosimilar KL 140","Cetuximab-cetu","Chimeric Anti-EGFR Monoclonal Antibody","Chimeric MoAb C225","Chimeric Monoclonal Antibody C225","ENZ 124","ENZ-124","ENZ124","Erbitux","IMC-C225"],"type":"BIOLOGICAL"},{"name":"Encorafenib","otherNames":["Braftovi","LGX 818","LGX-818","LGX818"],"type":"DRUG"},{"name":"Nivolumab","otherNames":["ABP 206","BCD-263","BMS 936558","BMS-936558","BMS936558","CMAB819","MDX 1106","MDX-1106","MDX1106","NIVO","Nivolumab Biosimilar ABP 206","Nivolumab Biosimilar BCD-263","Nivolumab Biosimilar CMAB819","ONO 4538","ONO-4538","ONO4538","Opdivo"],"type":"BIOLOGICAL"}],"last_update":"2026-07-08","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-02-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years"}],"references":[],"start_date":{"date":"2022-07-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation","url":"https://clinicaltrials.gov/study/NCT05308446"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/swog-2107-nct05308446"}